logo-loader

Tissue Regenix strengthens management with development specialist

Published: 08:11 01 Oct 2012 EDT

no_picture_pai

Regenerative tissue specialist Tissue Regenix (LON:TRX) has further beefed up its senior management with the appointment of Rob Snell to oversee its development and manufacturing processes.

Snell joins from medical devices company Ranier Technology where he worked as technical director responsible for its Cadisc spinal implants.

His career spans 20 years developing devices in the fields of orthopaedics, cardiology, urology and thin film barrier products.

Tissue said the appointment part of its plan to accelerate the development of a range of products based on it dCELL technology, which allows human and animal tissue to be used as replacement body parts without rejection.

The company recently appointed Andrea Rausch as business development manager for Tissue Regenix’s cardiac products.

Antony Odell, Tissue Regenix’s managing director said: "We are delighted that Rob is joining our senior team to help us lead the expanded development team as we progress the development of our pipeline of products and applications based on the dCELL technology platform."

Shares rose 9% to 11.75p.


Tissue Regenix Group "has the opportunity to become a global commercial...

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022. They reveal their highlights from the year before looking ahead to what investors can expect from the...

on 02/02/2023